Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday
Omeros Corp OMER
$11.84
▼ -0.75%
($-0.09)
🔥 High Short Interest
🎢 High Beta
🗓️ Earnings Next Week
Open
$11.93
Prev Close
$11.93
Day Range
$11.37 – $11.99
52W Range
$3.44 – $17.65
Market Cap
$856.92M
P/E (TTM)
9.72
Beta
2.58
EPS (TTM)
$0.94
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2009-10-08 |
| Shares Out. | 72,380,000 |
| Website | omeros.com/ ↗ |
| Phone | 12066765000 |
| Employees | 175 |
| Revenue | $9.9M |
| Gross Profit | $9.3M |
| Net Income | $56.1M |
| Free Cash Flow | -$94.8M |
| Total Assets | $286.2M |
| Total Liabilities | $349.5M |
| Equity | -$63.3M |
About Omeros Corp
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros Corp is a publicly traded company under the ticker symbol OMER on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)